Abbreviated or standard antiplatelet therapy after percutaneous coronary intervention (PCI) in high bleeding risk (HBR) patients with chronic kidney disease: a prespecified analysis from the MASTER DAPT trial
Authors' conclusion
Abbreviated APT was associated with similar NACE and MACCE rates and reduced bleeding compared with standard APT in HBR patients undergoing PCI, regardless of the presence or absence of CKD.
Study context
- Population
- HBR patients undergoing PCI, with and without chronic kidney disease (CKD) (eGFR <60 mL/min/1.73 m²)1,428 [31%] with CKD
- Participants
- 4,579 patients
- Comparison
- Abbreviated vs standard antiplatelet therapy, by CKD status
- Primary endpoint
- Co-primary: NACE (all-cause death, MI, stroke, major bleeding); MACCE (all-cause death, MI, stroke); Bleeding Academic Research Consortium (BARC) 2, 3 or 5 bleeding
- Follow-up
- 11 months
Methodological detailsprespecified subgroup analysis
- Prespecified subgroup analysis
Primary result
As reported in the abstract
NACE, MACCE and BARC 2, 3 or 5 bleeding by CKD status (co-primary)
Abbreviated APT vs Standard APTHazard ratio (95% CI)
NACE, CKD
0.91(0.66–1.24)
NACE, non-CKD; interaction P=0.78
0.96(0.73–1.27)
BARC 2, 3 or 5 bleeding, CKD
0.74(0.52–1.07)
BARC 2, 3 or 5 bleeding, non-CKD; interaction P=0.59
0.66(0.51–0.85)
- MACCE did not differ, CKD: HR
- 0.91 (95% CI 0.64-1.27)
- MACCE did not differ, non-CKD: HR (95% CI 0.78-1.51); interaction P=0.45
- 1.09
Original publication
Abbreviated or standard antiplatelet therapy after PCI in HBR patients with chronic kidney disease: a prespecified analysis from the MASTER DAPT trial. EuroIntervention. Published 1 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →